Formation of the Terminal Complement Complex on Agarose Beads: Further Evidence that Vitronectin (Complement S‐Protein) Inhibits C9 Polymerization

Vitronectin occupies the metastable binding site of C5b‐7, which is unable to insert membranes as part of the complement lytic attack. Some evidence has been presented that vitronectin inhibits also membrane‐associated pore formation by inhibiting C9 polymerization in the terminal complement complex (TCC). The authors wished to add to this background by studying the effect of vitronectin on formation of TCC on a carbohydrate surface like agarose beads, an alternative complement pathway activator. Bound TCC was detected by monoclonal and polyclonal antibodies to C9‐neoepitopes. Soluble SC5b‐7 and TCC (SC5b‐9) did not bind to the agarose beads. Using serum or isolated complement factors for the alternative and terminal pathways, the authors found that vitronectin reduced the density of C9‐neoepitopes on the beads. As there was no convincing evidence for association of vitronectin with the factors C5b‐8 of the agarose‐bound TCC, it was concluded that vitronectin bound directly to C9 in TCC and inhibited C9 polymerization within the complex. The authors have shown that TCC can bind to a carbohydrate surface like agarose (an alternating polymer of galactose moieties) in the absence of lipid. These results suggest that vitronectin can limit the lytic effect of membrane‐bound TCC by inhibiting C9 polymerization.

[1]  B. Pussell,et al.  Vitronectin‐mediated inhibition of complement: evidence for different binding sites for C5b‐7 and C9 , 1993, Clinical and experimental immunology.

[2]  M. Harboe,et al.  Heparin-binding properties of vitronectin are linked to complex formation as illustrated by in vitro polymerization and binding to the terminal complement complex. , 1992, The Journal of biological chemistry.

[3]  H. Johnson,et al.  Human Umbilical Vein Endothelial Cells Synthesize S‐Protein (Vitronectin) In Vitro , 1992, Scandinavian journal of immunology.

[4]  K. Preissner,et al.  Complement S-protein (vitronectin) is associated with cytolytic membrane-bound C5b-9 complexes. , 1988, Clinical and experimental immunology.

[5]  M. Peitsch,et al.  The heparin binding domain of S-protein/vitronectin binds to complement components C7, C8, and C9 and perforin from cytolytic T-cells and inhibits their lytic activities. , 1988, Biochemistry.

[6]  G. Hetland,et al.  A sensitive method to detect synthesis of the functional classical, alternative and terminal pathway of complement by cells cultured in vitro. , 1988, Scandinavian journal of clinical and laboratory investigation.

[7]  R. Falk,et al.  Synthesis of Complement Components C5, C6, C7, C8 and C9 in Vitro by Human Monocytes and Assembly of the Terminal Complement Complex , 1986, Scandinavian journal of immunology.

[8]  J. Tschopp,et al.  Monoclonal Antibodies Recognizing a Neoantigen of Poly(C9) Detect the Human Terminal Complement Complex in Tissue and Plasma , 1985, Scandinavian journal of immunology.

[9]  H. Müller-Eberhard,et al.  The SC5b-7 complex: formation, isolation, properties, and subunit composition. , 1977, Journal of immunology.

[10]  S. Bhakdi,et al.  Preparation and isolation of specific antibodies to complement components. , 1983, Methods in enzymology.